Moderna (LTS:0A45) Other Current Liabilities : $834 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Other Current Liabilities?

Moderna's other current liabilities for the quarter that ended in Mar. 2024 was $834 Mil.

Moderna's quarterly other current liabilities increased from Sep. 2023 ($491 Mil) to Dec. 2023 ($842 Mil) but then declined from Dec. 2023 ($842 Mil) to Mar. 2024 ($834 Mil).

Moderna's annual other current liabilities increased from Dec. 2021 ($140 Mil) to Dec. 2022 ($243 Mil) and increased from Dec. 2022 ($243 Mil) to Dec. 2023 ($842 Mil).

Moderna Other Current Liabilities Historical Data

The historical data trend for Moderna's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Other Current Liabilities Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Moderna Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Moderna Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Moderna's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (LTS:0A45) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines